An investigational breast cancer vaccine produced an immune response in 74% of clinical trial participants, according to data being presented at the San Antonio Breast Cancer Symposium.
Cleveland Clinic researchers conducted the phase 1 clinical trial, which enrolled 35 patients across three cohorts, according to a Dec. 11 news release from the health system.
The three cohorts included: patients who completed treatment for early-stage, triple-negative breast cancer within the previous three years and were tumor-free but at high risk for recurrence; cancer-free individuals who carry genetic mutations associated with elevated breast cancer risk and elected to have a preventative mastectomy; and early-stage triple-negative breast cancer patients who received pre-operative chemoimmunotherapy and surgery, and were treated with pembrolizumab.
A phase 2 trial for the vaccine is expected to begin in 2026 and last two to three years, the release said.
Leave a Reply